Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE

Executive Summary

The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.

You may also be interested in...



Twin Intellia Readouts Further Bolster CRISPR Platform

The company presented interim data for NTLA-2002 in hereditary angioedema, along with interim data for Regeneron-partnered NTLA-2001 in transthyretin amyloidosis with cardiomyopathy. The company plans a rapid expansion of its programs.

BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales

Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.

Takeda Sees Mainstays Tiding It Over Upcoming Expiries

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel